Evaluation of serum calprotectin (MRP-8/MRP-14) levels in patients with juvenile idiopathic arthritis

Aim: To compare the levels of serum calprotectin (sCal) in patients with juvenile idiopathic arthritis (JIA) depending on the type of therapy to assess the disease activity comprehensively for further treatment correction. Material and methods: We determined the sCal levels in 74 JIA patients who h...

Full description

Bibliographic Details
Main Authors: Tetiana Marushko, Yuliia Holubovska, Yeva-Emiliia Kulchytska
Format: Article
Language:English
Published: Hygeia Press di Corridori Marinella 2021-03-01
Series:Journal of Pediatric and Neonatal Individualized Medicine
Subjects:
Online Access:https://jpnim.com/index.php/jpnim/article/view/863
_version_ 1818350493084155904
author Tetiana Marushko
Yuliia Holubovska
Yeva-Emiliia Kulchytska
author_facet Tetiana Marushko
Yuliia Holubovska
Yeva-Emiliia Kulchytska
author_sort Tetiana Marushko
collection DOAJ
description Aim: To compare the levels of serum calprotectin (sCal) in patients with juvenile idiopathic arthritis (JIA) depending on the type of therapy to assess the disease activity comprehensively for further treatment correction. Material and methods: We determined the sCal levels in 74 JIA patients who had normal C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) levels. High-sensitivity C-reactive protein was evaluated in 16 patients. All children were divided into 2 groups depending on the type of therapy. Group I consisted of 33 children on methotrexate (MTX) therapy, 11 of which were in the state of clinical pharmacologic remission. Group II included 41 children treated with biological Disease-Modifying Antirheumatic Drugs (bDMARDs), 14 of which achieved the state of clinical pharmacologic remission. A results analysis was carried out according to the Mann-Whitney U test. A Spearman rank correlation was performed to define the type of correlation between the indicators. Results: sCal level was 5.5 times higher in patients with JIA (3,300 μg/L), compared with healthy children (600 μg/L) (p = 0.015). The highest sCal level observed was among the patients in Group I, who received MTX exclusively both in the active phase of the disease (U = 71.5, p = 0.000006) and in the state of clinical pharmacologic remission (U = 11, p = 0.00034). There was a moderate positive correlation of sCal level and disease activity indices, such as the 27-joint Juvenile Arthritis Disease Activity Score (JADAS27) (Spearman’s rho = 0.58, p = 0.0001) and high-sensitivity CRP (Spearman’s rho = 0.56, p = 0.024). Conclusions: sCal levels should be used to monitor the subclinical inflammatory activity in patients with JIA. The use of bDMARDs in JIA treatment is effective.
first_indexed 2024-12-13T18:22:43Z
format Article
id doaj.art-470065ebd0164fdda3726ab92071d607
institution Directory Open Access Journal
issn 2281-0692
language English
last_indexed 2024-12-13T18:22:43Z
publishDate 2021-03-01
publisher Hygeia Press di Corridori Marinella
record_format Article
series Journal of Pediatric and Neonatal Individualized Medicine
spelling doaj.art-470065ebd0164fdda3726ab92071d6072022-12-21T23:35:40ZengHygeia Press di Corridori MarinellaJournal of Pediatric and Neonatal Individualized Medicine2281-06922021-03-01101e100140e10014010.7363/100140727Evaluation of serum calprotectin (MRP-8/MRP-14) levels in patients with juvenile idiopathic arthritisTetiana Marushko0Yuliia Holubovska1Yeva-Emiliia Kulchytska2Department of Paediatrics No. 2, Shupyk National Healthcare University of Ukraine, Kyiv, UkraineDepartment of Paediatrics No. 2, Shupyk National Healthcare University of Ukraine, Kyiv, UkraineDepartment of Paediatrics No. 2, Shupyk National Healthcare University of Ukraine, Kyiv, UkraineAim: To compare the levels of serum calprotectin (sCal) in patients with juvenile idiopathic arthritis (JIA) depending on the type of therapy to assess the disease activity comprehensively for further treatment correction. Material and methods: We determined the sCal levels in 74 JIA patients who had normal C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) levels. High-sensitivity C-reactive protein was evaluated in 16 patients. All children were divided into 2 groups depending on the type of therapy. Group I consisted of 33 children on methotrexate (MTX) therapy, 11 of which were in the state of clinical pharmacologic remission. Group II included 41 children treated with biological Disease-Modifying Antirheumatic Drugs (bDMARDs), 14 of which achieved the state of clinical pharmacologic remission. A results analysis was carried out according to the Mann-Whitney U test. A Spearman rank correlation was performed to define the type of correlation between the indicators. Results: sCal level was 5.5 times higher in patients with JIA (3,300 μg/L), compared with healthy children (600 μg/L) (p = 0.015). The highest sCal level observed was among the patients in Group I, who received MTX exclusively both in the active phase of the disease (U = 71.5, p = 0.000006) and in the state of clinical pharmacologic remission (U = 11, p = 0.00034). There was a moderate positive correlation of sCal level and disease activity indices, such as the 27-joint Juvenile Arthritis Disease Activity Score (JADAS27) (Spearman’s rho = 0.58, p = 0.0001) and high-sensitivity CRP (Spearman’s rho = 0.56, p = 0.024). Conclusions: sCal levels should be used to monitor the subclinical inflammatory activity in patients with JIA. The use of bDMARDs in JIA treatment is effective.https://jpnim.com/index.php/jpnim/article/view/863juvenile idiopathic arthritisserum calprotectinmethotrexatebiological dmards
spellingShingle Tetiana Marushko
Yuliia Holubovska
Yeva-Emiliia Kulchytska
Evaluation of serum calprotectin (MRP-8/MRP-14) levels in patients with juvenile idiopathic arthritis
Journal of Pediatric and Neonatal Individualized Medicine
juvenile idiopathic arthritis
serum calprotectin
methotrexate
biological dmards
title Evaluation of serum calprotectin (MRP-8/MRP-14) levels in patients with juvenile idiopathic arthritis
title_full Evaluation of serum calprotectin (MRP-8/MRP-14) levels in patients with juvenile idiopathic arthritis
title_fullStr Evaluation of serum calprotectin (MRP-8/MRP-14) levels in patients with juvenile idiopathic arthritis
title_full_unstemmed Evaluation of serum calprotectin (MRP-8/MRP-14) levels in patients with juvenile idiopathic arthritis
title_short Evaluation of serum calprotectin (MRP-8/MRP-14) levels in patients with juvenile idiopathic arthritis
title_sort evaluation of serum calprotectin mrp 8 mrp 14 levels in patients with juvenile idiopathic arthritis
topic juvenile idiopathic arthritis
serum calprotectin
methotrexate
biological dmards
url https://jpnim.com/index.php/jpnim/article/view/863
work_keys_str_mv AT tetianamarushko evaluationofserumcalprotectinmrp8mrp14levelsinpatientswithjuvenileidiopathicarthritis
AT yuliiaholubovska evaluationofserumcalprotectinmrp8mrp14levelsinpatientswithjuvenileidiopathicarthritis
AT yevaemiliiakulchytska evaluationofserumcalprotectinmrp8mrp14levelsinpatientswithjuvenileidiopathicarthritis